Sign In
Buy ALGS
$4.23
-0.0900 (-2.08%)
At Close: Jul 31, 2026
Are Medical Stocks Lagging Aligos Therapeutics (ALGS) This Year?
10:46am, Tuesday, 10'th Sep 2024
Here is how Aligos Therapeutics, Inc. (ALGS) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%
10:55am, Wednesday, 21'st Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 648.1% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionabl
Aligos Therapeutics Announces Reverse Stock Split
09:00am, Thursday, 15'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on developing n
What Makes Aligos Therapeutics (ALGS) a New Buy Stock
01:01pm, Friday, 09'th Aug 2024
Aligos Therapeutics (ALGS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aligos Therapeutics Strengthens Board with Two New Independent Directors
04:05pm, Thursday, 08'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on develo
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
09:00am, Monday, 22'nd Jul 2024
Amoytop to sponsor a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING® (Mipeginterferon alfa-2b) in CHB patients
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
08:00am, Wednesday, 10'th Jul 2024
SOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
02:30am, Wednesday, 05'th Jun 2024
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeuti
Here's Why Aligos Therapeutics (ALGS) Is a Great 'Buy the Bottom' Stock Now
10:56am, Tuesday, 04'th Jun 2024
Aligos Therapeutics (ALGS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
08:30am, Wednesday, 29'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #PFIC--Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress.
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
04:05pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutic
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
08:00am, Tuesday, 21'st May 2024
Topline data now projected in early Q4 2024 Rohit Loomba, MD, MHSc to serve as Principal Investigator SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: A
After Plunging -13.71% in 4 Weeks, Here's Why the Trend Might Reverse for Aligos Therapeutics (ALGS)
10:36am, Thursday, 16'th May 2024
Aligos Therapeutics (ALGS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
04:05pm, Tuesday, 30'th Apr 2024
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeut
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
04:05pm, Thursday, 25'th Apr 2024
Data demonstrates a 7-day treatment regimen with the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting
